Galderma Group N Asset Resilience Ratio

Latest as of June 2025: 3.56%

Galderma Group N asset resilience ratio. Galderma Group N (GALD) has an Asset Resilience Ratio of 3.56% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GALD defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CHF458.00 Million

≈ $579.04 Million USD Cash + Short-term Investments

Total Assets

CHF12.88 Billion

≈ $16.28 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Galderma Group N (2021–2024)

Asset resilience ratio of Galderma Group N from 2021 to 2024. This chart shows how Galderma Group N's Asset Resilience Ratio has changed over time. Read Galderma Group N total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Galderma Group N's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GALD current and non-current assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF458.00 Million	3.56%
Short-term Investments	CHF0.00	0%
Total Liquid Assets	CHF458.00 Million	3.56%

Asset Resilience Insights

Limited Liquidity: Galderma Group N maintains only 3.56% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Galderma Group N Industry Peers by Asset Resilience Ratio

Compare Galderma Group N's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Zhejiang Nhu Co Ltd SHE:002001	Drug Manufacturers - Specialty & Generic	4.97%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt F:RIG2	Drug Manufacturers - Specialty & Generic	0.20%
Beijing Tongrentang Co Ltd SHG:600085	Drug Manufacturers - Specialty & Generic	2.51%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	9.04%
Tianjin Zhongxin Pharmaceutical Group Corp Ltd SHG:600329	Drug Manufacturers - Specialty & Generic	5.92%
Neuland Laboratories Limited NSE:NEULANDLAB	Drug Manufacturers - Specialty & Generic	9.65%
Zhejiang Xianju Pharmaceutical Co Ltd SHE:002332	Drug Manufacturers - Specialty & Generic	6.02%

Galderma Group N Asset Resilience Ratio by Year (2021–2024)

Galderma Group N asset resilience ratio by year from 2021 to 2024. The table below shows the annual Asset Resilience Ratio data for Galderma Group N.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	2.64%	CHF333.59 Million ≈ $421.75 Million	CHF12.62 Billion ≈ $15.95 Billion	+0.41pp
2023-12-31	2.23%	CHF234.26 Million ≈ $296.17 Million	CHF10.49 Billion ≈ $13.26 Billion	+2.23pp
2022-12-31	0.00%	CHF185.04K ≈ $233.94K	CHF11.49 Billion ≈ $14.52 Billion	-0.02pp
2021-12-31	0.02%	CHF2.46 Million ≈ $3.11 Million	CHF11.45 Billion ≈ $14.48 Billion	--

pp = percentage points

About Galderma Group N

SW:GALD Switzerland Drug Manufacturers - Specialty & Generic

Market Cap

$55.98 Billion

CHF44.28 Billion CHF

Market Cap Rank

#733 Global

#12 in Switzerland

Share Price

CHF188.55

Change (1 day)

-1.10%

52-Week Range

CHF142.10 - CHF195.15

All Time High

CHF195.15